-
Education, Training, & Certifications
-
-
-
Leadership & Clinical Positions at Duke
-
Director, Pediatrics Epilepsy Monitoring Unit
Co- Director Tuberous sclerosis clinic
-
Subject Headings
-
Selected Grants
-
A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated with Epidiolex (Cannabidiol) Oral Solution
awarded by GW Research Limited
2021 - 2031
-
LivaNova Core Registry
awarded by LivaNova
2019 - 2026
-
Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-onset (Focal) Seizures"
awarded by SK Life Science, Inc
2022 - 2025
-
Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep
awarded by Neurocrine Biosciences, Inc.
2022 - 2024
-
Hartwell Individual Biomedical Research Award
awarded by Hartwell Foundation
2021 - 2024
-
Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wav
awarded by Neurocrine Biosciences, Inc.
2021 - 2023
-
1042-TSC-2001 - Marinus TSC
awarded by Marinus Pharmaceuticals, Inc.
2020 - 2023
-
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETICS STUDY OF VALTOCO® WITH OPEN-LABEL SAFETY PERIOD IN PEDIATRIC SUBJECTS WITH EPILEPSY
awarded by Neurelis, Inc
2022 - 2023
-
An Observational Study to Investigate Cognition and Quality of Life in Children and Adolescents with Dravet Syndrome (Pro00102865)
awarded by Stoke Therapeutics, Inc.
2019 - 2023
-
A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment
awarded by Marinus Pharmaceuticals, Inc.
2019 - 2023
-
An open-label, long-term safety and tolerability study of b1ivaracetam as adjunctive treatment in pediatric study participants with epilepsy
awarded by UCB Biopharma
2021 - 2023
-
Microburst VNS Therapy Feasibility Study in Subjects with Refractory Epilepsy
awarded by LivaNova
2019 - 2022
-
Phase I, Open-Label, Pharmacokinetic, Dose Escalation Study of Carisbamate in Adult and Pediatric Subjects with Lennox-Gastaut Syndrome
awarded by SK Life Science, Inc
2019 - 2022
-
OPEN-LABEL, SINGLE-ARM, MULTICENTER, LONG-TERM
STUDY TO EVALUATE SAFETY AND EFFICACY OF
BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN
PEDIATRIC SUBJECTS WITH EPILEPSY
awarded by UCB Pharma, Inc.
2018 - 2022
-
Study of Oral Pyridoxal 5'-Phosphate for the Treatment of Patients with PNPO Deficiency
awarded by Medicure, Inc.
2021 - 2022
-
E2007-G000-238 Perampanel for <2 yrs
awarded by Eisai, Inc.
2019 - 2022
-
A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and Pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients
awarded by Bio-Pharm Solutions Co., Ltd.
2020 - 2021
-
A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF INTRAVENOUS BRIVARACETAM IN SUBJECTS ¿1 MONTH TO <16 YEARS OF AGE WITH EPILEPSY
PHASE 2
awarded by UCB Pharma, Inc.
2018 - 2021
-
Phase I, Open-Label Study of Carisbamate in Adult and Pediatric Subjects with Lennox-Gastaut Syndrome
awarded by SK Life Science, Inc
2020 - 2021
-
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WITH EPILEPSY >1 MONTH TO <4 YEARS OF AGE WITH PARTIAL-ONSET SEIZURES
awarded by UCB Biosciences Inc.
2019 - 2021
-
A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF
LACOSAMIDE AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS WITH EPILEPSY WITH PARTIAL-ONSET SEIZURES PHASE 3
awarded by UCB Biosciences Inc.
2019 - 2020
-
A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by Long-term Open-label Treatment
awarded by Marinus Pharmaceuticals, Inc.
2018 - 2020
-
A Two-Part Study of ZX008 in Children and Adults with Lennox-Gastaut Syndrome (LGS)
awarded by Zogenix International Limited
2019 - 2020
-
A Retrospective Multicenter Study to Investigate Dosage, Efficacy,and Safety of Fycompa® in Routine Clinical Care of Patients With
Epilepsy
awarded by Eisai, Inc.
2018 - 2019
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.
